耐药性癌细胞 z-bo 2020-09-30 374

　　In the latest research report published in the international journal Molecular Cell, scientists from Trinity College Dublin and other institutions have explored many new biological targets by studying and understanding the internal network of genes related to cell identity, which will help Researchers develop new alternative therapies to treat a variety of cancers that are resistant to current drugs.

　　Polycombgenes was first discovered in fruit flies. Because of its important role in development and its importance in regulating cell identity, scientists have studied it for the first time. This gene is the field of epigenetics research. In 2011, scientists discovered EZH2, a special polycomb gene that is mutated in lymphoma cells. Due to years of research by scientists, some companies quickly developed inhibitory EZH2 activity. Drugs, how these targeted therapies show specific potential in clinical trials. However, with the development and application of various cancer treatment methods, the drug resistance of cancer cells has also begun to appear, and scientists urgently need to develop new drug-resistant cell treatment methods. I will. In this study, the researchers found that EZH2 requires additional other components to target the activity of key regions of the genome while performing important cellular functions. More importantly, these add-ons represent very potential alternative targets. These goals can be used to develop new therapies to treat cancer patients who are resistant to current EZH2 inhibitors.

　　Researcher Professor Brecon said that the findings in this article are based on the study of the mechanism by which polycomb genes regulate cell identity, and the development of alternative therapies to treat mutant EZH2 and related genes. I guess it will provide new opportunities. cancer patient. Subsequent researchers will also conduct in-depth research to develop new strategies or treatments to combat drug-resistant cancer.